225 related articles for article (PubMed ID: 31874070)
1. Comparative Approaches to Drug Pricing.
Kang SY; Bai G; DiStefano MJ; Socal MP; Yehia F; Anderson GF
Annu Rev Public Health; 2020 Apr; 41():499-512. PubMed ID: 31874070
[TBL] [Abstract][Full Text] [Related]
2. Impact of European pharmaceutical price regulation on generic price competition: a review.
Puig-Junoy J
Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
[TBL] [Abstract][Full Text] [Related]
3. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
Raimond VC; Feldman WB; Rome BN; Kesselheim AS
Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
[TBL] [Abstract][Full Text] [Related]
4. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
Davidova J; Praznovcova L; Lundborg CS
Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
[TBL] [Abstract][Full Text] [Related]
5. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
6. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
Schlette S; Hess R
Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
[TBL] [Abstract][Full Text] [Related]
7. Regulation of pharmaceutical prices: evidence from a reference price reform in Denmark.
Kaiser U; Mendez SJ; Rønde T; Ullrich H
J Health Econ; 2014 Jul; 36():174-87. PubMed ID: 24879578
[TBL] [Abstract][Full Text] [Related]
8. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
Vacca C; Acosta A; Rodriguez I
Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
[TBL] [Abstract][Full Text] [Related]
9. Using External Reference Pricing In Medicare Part D To Reduce Drug Price Differentials With Other Countries.
Kang SY; DiStefano MJ; Socal MP; Anderson GF
Health Aff (Millwood); 2019 May; 38(5):804-811. PubMed ID: 31059372
[TBL] [Abstract][Full Text] [Related]
10. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
Danzon PM; Towse A
Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
[TBL] [Abstract][Full Text] [Related]
11. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
12. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
Hernandez I; San-Juan-Rodriguez A; Good CB; Gellad WF
JAMA; 2020 Mar; 323(9):854-862. PubMed ID: 32125403
[TBL] [Abstract][Full Text] [Related]
13. Implications of external price referencing of pharmaceuticals in Middle East countries.
Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical cost containment and innovation in the United States.
Kane NM
Health Policy; 1997 Sep; 41 Suppl():S71-89. PubMed ID: 10174475
[TBL] [Abstract][Full Text] [Related]
15. Effects of regulation on drug launch and pricing in interdependent markets.
Danzon PM; Epstein AJ
Adv Health Econ Health Serv Res; 2012; 23():35-71. PubMed ID: 23156660
[TBL] [Abstract][Full Text] [Related]
16. Challenges in the Regulation of High-Cost Treatments: An Overview From Brazil.
Pereira LC; Sturzenegger DVR; Ortiz J; Ayad NME; Cortopassi WA; Safatle LP; Khuri N
Value Health Reg Issues; 2019 Dec; 20():191-195. PubMed ID: 31733406
[TBL] [Abstract][Full Text] [Related]
17. External Reference Pricing for Pharmaceuticals-A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage.
Holtorf AP; Gialama F; Wijaya KE; Kaló Z
Value Health Reg Issues; 2019 Sep; 19():122-131. PubMed ID: 31416014
[TBL] [Abstract][Full Text] [Related]
18. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
19. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
[TBL] [Abstract][Full Text] [Related]
20. The determinants of pricing in pharmaceuticals: are US prices really so high?
Cabrales A; Jiménez-Martín S
Health Econ; 2013 Nov; 22(11):1377-97. PubMed ID: 23303712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]